$310 Million is the total value of Knoll Capital Management, LLC's 19 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was 47.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDVN | Medivation, Inc. | $251,117,000 | -11.5% | 2,198,919 | 0.0% | 80.96% | -2.0% | |
| SYN | Synthetic Biologics Inc. | $9,692,000 | +30.1% | 3,400,816 | 0.0% | 3.12% | +44.1% | |
| AMPE | Ampio Pharmaceuticals Inc. | $8,098,000 | -68.3% | 3,388,322 | 0.0% | 2.61% | -64.9% | |
| ADHD | Alcobra Ltd | $7,294,000 | +16.2% | 1,115,315 | 0.0% | 2.35% | +28.6% | |
| ABEO | New | Abeona Therapeutics Inc | $6,880,000 | – | 1,359,767 | +100.0% | 2.22% | – |
| New | Advaxis Inc. | $5,591,000 | – | 275,000 | +100.0% | 1.80% | – | |
| CRBP | New | Corbus Pharmaceuticals HLDGS | $5,390,000 | – | 1,750,000 | +100.0% | 1.74% | – |
| NLNK | Newlink Genetics Corp | $4,535,000 | -19.1% | 102,437 | 0.0% | 1.46% | -10.4% | |
| ORPN | Bio Blast Pharma Ltd | $2,330,000 | +14.8% | 338,110 | 0.0% | 0.75% | +27.1% | |
| KERX | Keryx Biopharmaceuticals Inc. | $1,996,000 | -21.6% | 200,000 | 0.0% | 0.64% | -13.2% | |
| CLBS | New | Caladrius Biosciences Inc | $1,870,000 | – | 1,000,000 | +100.0% | 0.60% | – |
| New | Advaxis Inc.w exp 07/15/201 | $1,749,000 | – | 112,500 | +100.0% | 0.56% | – | |
| ALDX | Aldeyra Therapeutics Inc | $1,054,000 | -23.7% | 135,800 | 0.0% | 0.34% | -15.4% | |
| LBIO | Sell | Lion Biotechnologies Inc | $890,000 | -26.5% | 97,100 | -2.9% | 0.29% | -18.7% |
| GLMD | Galmed Pharmaceuticals Ltd | $654,000 | +6.9% | 65,000 | 0.0% | 0.21% | +18.5% | |
| OHRP | OHR Pharmaceutical Inc | $515,000 | -1.2% | 205,000 | 0.0% | 0.17% | +9.2% | |
| EVOK | Buy | Evoke Pharma Inc | $291,000 | -23.4% | 55,660 | +3.4% | 0.09% | -15.3% |
| ZSAN | Zosano Pharma Corp | $145,000 | -28.2% | 20,000 | 0.0% | 0.05% | -20.3% | |
| Aptose Biosciences Inc | $102,000 | -5.6% | 20,000 | 0.0% | 0.03% | +6.5% | ||
| PTBI | Exit | PlasmaTech Biopharmaceutical | $0 | – | -213,100 | -100.0% | -0.20% | – |
| ADXSW | Exit | Advaxis Inc.w exp 07/15/201 | $0 | – | -112,500 | -100.0% | -0.34% | – |
| ADXS | Exit | Advaxis Inc. | $0 | – | -275,000 | -100.0% | -1.16% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
| 13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.